Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Lung Neoplasms × Triamcinolone Acetonide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Radiodermatitis 1 Mycosis Fungoides 1 Lymphoma, T-Cell, Cutaneous 1 Lung Neoplasms 1 Glioblastoma 1 Exanthema 1 Dermatitis, Contact 1 Castration Resistant Prostate Cancer 1 Breast Neoplasms 1

Interventions

Carboplatin 195 Cisplatin 117 Paclitaxel 107 Pemetrexed 106 Docetaxel 96 Gemcitabine 88 Radiotherapy 83 Erlotinib Hydrochloride 58 Bevacizumab 55 Etoposide 49 pembrolizumab 38 durvalumab 38 Specimen Handling 29 Nivolumab 29 Magnetic Resonance Spectroscopy 28 Irinotecan 27 Radiosurgery 26 osimertinib 24 Gefitinib 24 Vinorelbine 22 Drug Therapy 22 atezolizumab 20 Topotecan 20 Radiation 16 Cetuximab 16 Taxes 15 Surgical Procedures, Operative 14 Neoadjuvant Therapy 13 Filgrastim 13 Chemotherapy, Adjuvant 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00473083 2017-04-04

LUTRAERL

British Columbia Cancer Agency

Phase 2 Completed

150 enrolled 13 charts

Exanthema, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡